MRKR - Marker Therapeutics Inc
Marker Therapeutics Inc Logo

MRKR - Marker Therapeutics Inc

https://markertherapeutics.com
Recent News
Powered by Alpha Vantage
Bullish
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - Marker Therapeutics ( NASDAQ:MRKR )
Benzinga • 2 weeks, 4 days ago • score: 0.25
HOUSTON, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. MRKR, a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.

52W High
$5.95
52W Low
$0.81
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.52
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.22
EV/Revenue (<3 favorable)
0.17
P/S (TTM) (<3 favorable)
2.15
P/B (<3 favorable)
1.11
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
7.08%
Institutions (25–75% balanced)
26.37%
Shares Outstanding
12,938,900
Float
10,386,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
5,388,100
Gross Profit (TTM)
-10,481,809
EPS (TTM)
-1.35
Profit Margin (>10% good)
-2.71%
Operating Margin (TTM) (higher better)
-4.95%
ROE (TTM) (>15% strong)
-1.45%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.26
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—